The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company, BMS, to test a novel investigational drug, BMS-986165
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
PD-L1 is involved in the body’s immune response to cancer and nivolumab demonstrates better effectiveness in patients who have more PD-L1 protein on their cancer cells.